{"denoms":[{"counts":[{"groupId":"BG000","value":"6"}],"units":"Participants"}],"groups":[{"description":"All participants enrolled.\n\nBortezomib (Velcade): Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 4, 8, and 11 q. 21 days times three cycles.\n\nPatients will undergo three 21-day cycles.","id":"BG000","title":"All Patients"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.58","value":"71"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}